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Diagnosing and delineating the thresholds for “adrenal insufficiency” in critical illness is still 
the subject of many manuscripts, hours of conference time and the subject of “position 
statements” [1]. This is because the existence of the disorder, how to diagnose it (if it exists) 
and how to treat it are still controversial. The fundamental problem in moving towards 
answering these questions is that we still do not have an accurate model for HPA axis function 
in critical illness. The linked paper by Mongardon and colleagues[2] adds another small piece 
to the jigsaw, but in the process, it illustrates many of the reasons we still haven’t made 
forward progress. The rationale for performing the study was after Jung et al [3] who showed 
that patients with septic shock, who did not have enlarged adrenal glands, were at an 
increased risk of death. The proposed hypothesis being that those with a large inflammatory 
stimulus should have increased arterial flow to the adrenals and in the context of a fixed 
venous drainage this would lead to engorgement. 
 
The authors in the linked study in this issue of Resuscitation analysed 138 suitable admission 
CT scans from 775 patients admitted to one intensive care unit (ICU) after out-of-hospital-
cardiac arrest (OHCA). Two radiologists calculated adrenal volume and attempts were made 
to correlate these with available tests of adrenal function and outcomes. The CT scans had a 
median time from return of spontaneous circulation (ROSC) to scan of 3 hrs (IQR 2.5-4.5). This 
is very early for development of any adrenal dysfunction and is probably only the very 
beginning of being able to detect neuro-humoral inflammatory changes after an index 
event[4,5]. It therefore seems an early point to choose a snapshot view of an inflammatory 
process. The CT scans in the cited Jung et al study[3] were within 48 hrs of admission – but 
given the insidious onset of sepsis, this is likely to be some time after the onset of the illness 
and this is probably one reason for the differences seen. This illustrates the first point about 
HPA-axis function in critical illness; critical illness is a continuum and the point at which the 
HPA-axis function is observed is important. The changes that occur on the day of critical illness 
onset are not the same as those on the fifth day, which again are different from those on the 
twentieth – yet much of the literature treats critical illness as a single, unchanging entity.  
 
The authors make an attempt to correlate both cortisol and co-syntropin tests (if performed) 
with adrenal gland volume, although the absolute and relative number of patients in which 
this was achieved was quite low. The Mongardon study[2] (as do many others) take these 
tests and use them as a reference for other markers of poor adrenal function (in this case – 
adrenal volume).  The temporal relationship of the tests to the observed adrenal volume is 
not clear, but more importantly, the place of these two tests to diagnose “adrenal 
insufficiency” has still not been validated and it is therefore not logical to use them as a 
comparative reference for inadequate adrenal function. With regard to point plasma cortisol 
samples, there is substantial evidence that both cortisol and ACTH are pulsatile, with 
amplitudes of up to 400nmol/L in health[6,7], after major surgery[4] and in chronic[8] and 
critical illness[9]. The oscillations of cortisol are so large in this context that measuring point 
cortisol values gives us no indication of what the concentration may be even 30 minutes 
later[10]. Compounding this is that aggregating these pulsatile profiles leads to smooth 
lines[4]. Therefore, there is a situation in which the model for the aggregated population 
bears no resemblance to the individuals within that population – yet in much clinical research 
and practice, we apply the population model to the individual. 
 
Using a dynamic test such as a co-syntropin stimulation test is unlikely to be useful as well. 
Persistent negative feedback to the pituitary from circulating high levels of cortisol will reduce 
secretion of adreno-cortico-trophic hormone (ACTH) with a consequently negative trophic 
effect on the adrenals[4,9,11]. This is likely to take at least a few days to develop but will 
eventually reduce the size of the adrenal glands. It also means that using a co-syntropin test 
to diagnose insufficiency may in fact be treating the disorder it is trying to diagnose.  Adrenal 
sensitivity to ACTH can also change after acute inflammatory insults[4]. It would seem 
sensible to modify the thresholds of a co-syntropin test in this context – but yet this is not 
done[1]. Co-syntropin was licenced before the introduction of tight drug regulations and 
there are no studies informing us as to what plasma levels 250μg of co-syntropin achieve in a 
normal adult in health[12], let alone critical illness. All of these make it difficult to interpret 
its result. Additionally, the reduced cortisol metabolism seen in critical illness[13] means that 
circulating cortisol concentrations are potentially higher than in health regardless of whether 
they respond to a stimulus or not. The validation of these tests, in the middle of the 20th 
century, were designed for the outpatient setting and not the critically ill, but yet are still 
used.  
 
Treating critical illness as one disease process rather than delineating between different 
underlying causes also leads to confusion within the literature, although not in this case. 
There is a difference between the point inflammatory insult of cardiac arrest and the ongoing 
stimulus of sepsis. The disease course and outcomes are sufficiently different[14,15] for the 
HPA axis response not to be treated as a singular.  
 
A more rational approach to understanding the HPA-axis is required. The persistence in 
performing clinical studies and therapeutic drug trials without an accurate, longitudinal 
model of dynamic HPA-axis function in the critically ill will not yield the information we need 
to answer our questions, nor provide us with a robust baseline to design diagnostic and 
therapeutic studies. Carefully observing what happens in these different subsets of patients 
may be regarded as a retrograde step but is what is needed. In this regard, Mongardon and 
colleagues’ study adds value. 
 
References 
[1] Annane D, Pastores SM, Rochwerg B, Arlt W, Balk RA, Beishuizen A, et al. 
Guidelines for the Diagnosis and Management of Critical Illness-Related 
Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of 
Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine 
(ESICM) 2017. Crit Care Med 2017; 45: 1751-63 
[2] Mongardon N, Savary G, Geri G, El-Bejjani MR, Silvera S, Dumas F, Charpentier J, 
Pene F, Mira J-P, Cariou A. Prognostic value of adrenal gland volume after 
cardiac arrest: association of CT-scan evaluation with shock and mortality. 
Resuscitation – This issue. 
[3] Jung B, Nougaret S, Chanques G, Mercier G, Cisse M, Aufort S, et al. The 
absence of adrenal gland enlargement during septic shock predicts mortality: a 
computed tomography study of 239 patients. Anesthesiology 2011;115:334–43.  
[4] Gibbison B, Spiga F, Walker JJ, Russell GM, Stevenson K, Kershaw Y, et al. 
Dynamic pituitary-adrenal interactions in response to cardiac surgery. Crit Care 
Med 2015;43:791–800.  
[5] Caputo M, Alwair H, Rogers CA, Ginty M, Monk C, Tomkins S, et al. Myocardial, 
inflammatory, and stress responses in off-pump coronary artery bypass graft 
surgery with thoracic epidural anesthesia. Ann Thorac Surg 2009;87:1119–26.  
[6] Henley DE, Leendertz JA, Russell GM, Wood SA, Taheri S, Woltersdorf WW, et 
al. Development of an automated blood sampling system for use in humans. J 
Med Eng Technol 2009;33:199–208.  
[7] Veldhuis JD, Iranmanesh A, Lizarralde G, Johnson ML. Amplitude modulation of 
a burstlike mode of cortisol secretion subserves the circadian glucocorticoid 
rhythm. Am J Physiol 1989;257:E6–14. 
[8] Henley DE, Russell GM, Douthwaite JA, Wood SA, Buchanan F, Gibson R, et al. 
Hypothalamic-pituitary-adrenal axis activation in obstructive sleep apnea: the 
effect of continuous positive airway pressure therapy. J Clin Endocrinol Metab 
2009;94:4234–42.  
[9] Boonen E, Meersseman P, Vervenne H, Meyfroidt G, Guïza F, Wouters PJ, et al. 
Reduced nocturnal ACTH-driven cortisol secretion during critical illness. Am J 
Physiol Endocrinol Metab 2014;306:E883–92.  
[10] Powell B, Nason GP, Angelini GD, Lightman SL, Gibbison B. Optimal Sampling 
Frequency of Serum Cortisol Concentrations After Cardiac Surgery. Crit Care 
Med 2017;45:e1103–4.  
[11] Boonen E, Bornstein SR, Van den Berghe G. New insights into the controversy of 
adrenal function during critical illness. The Lancet Diabetes & Endocrinology 
2015;3:805–15.  
[12] Mallinckrodt UK Ltd. Medical Information Team. Personal Communication. 
Recived 23rd April 2018. 
[13] Boonen E, Vervenne H, Meersseman P, Andrew R, Mortier L, Declercq PE, et al. 
Reduced Cortisol Metabolism during Critical Illness. N Engl J Med 2013.  
[14] Nolan JP, Ferrando P, Soar J, Benger J, Thomas M, Harrison DA, et al. Increasing 
survival after admission to UK critical care units following cardiopulmonary 
resuscitation. Crit Care 2016;20:219. 
[15]  ICNARC Case Mix Programme Report. Length of stay, survival and organ 
support of admissions with septic shock to adult, general critical care units in 
England, Wales and Northern Ireland. (Accessed 3rd June 2018 Available from: 
https://www.icnarc.org/Our-Audit/Audits/Cmp/Our-National-Analyses/Sepsis. ) 
 
Conflicts of Interest 
None 
Sources of Funding 
Dr Gibbison is supported by the NIHR Biomedical Research Centre at University Hospitals 
Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this 
publication are those of the author(s) and not necessarily those of the NHS, the National 
Institute for Health Research or the Department of Health and Social Care.  
Competing interests 
None 
Acknowledgments 
None 
